Shiraz Shabanali Ladiwala Acquires 3,500 Shares of Mesa Laboratories (NASDAQ:MLAB) Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) Director Shiraz Shabanali Ladiwala acquired 3,500 shares of the stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average cost of $72.23 per share, with a total value of $252,805.00. Following the completion of the transaction, the director owned 8,523 shares in the company, valued at approximately $615,616.29. This represents a 69.68% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Mesa Laboratories Stock Up 10.1%

Mesa Laboratories stock opened at $80.60 on Thursday. Mesa Laboratories, Inc. has a 12-month low of $55.45 and a 12-month high of $131.20. The company has a market capitalization of $444.91 million, a PE ratio of 125.94 and a beta of 0.85. The firm’s fifty day moving average is $87.40 and its 200 day moving average is $78.22. The company has a quick ratio of 1.45, a current ratio of 1.94 and a debt-to-equity ratio of 0.86.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Tuesday, February 3rd. The medical instruments supplier reported $3.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.41 by $0.66. Mesa Laboratories had a return on equity of 22.02% and a net margin of 1.51%.The business had revenue of $65.13 million for the quarter, compared to analyst estimates of $63.23 million. As a group, sell-side analysts predict that Mesa Laboratories, Inc. will post 8 EPS for the current fiscal year.

Mesa Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 16th. Shareholders of record on Saturday, February 28th will be paid a dividend of $0.16 per share. The ex-dividend date is Friday, February 27th. This represents a $0.64 annualized dividend and a yield of 0.8%. Mesa Laboratories’s dividend payout ratio (DPR) is 100.00%.

Analyst Upgrades and Downgrades

MLAB has been the subject of a number of recent analyst reports. Wall Street Zen upgraded Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 7th. Zacks Research raised shares of Mesa Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. Weiss Ratings restated a “sell (d)” rating on shares of Mesa Laboratories in a report on Thursday, January 22nd. Finally, Wells Fargo & Company increased their target price on shares of Mesa Laboratories from $83.00 to $94.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 4th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $94.00.

Key Stories Impacting Mesa Laboratories

Here are the key news stories impacting Mesa Laboratories this week:

• Positive Sentiment: Several directors bought meaningful stakes this week (Shiraz S. Ladiwala 3,500 shares ~ $72.23, R. Tony Tripeny 1,315 shares ~ $76.00, Mark C. Capone 1,301 shares ~ $76.35). Multiple insider buys at these levels signal management confidence and can be interpreted as a bullish catalyst. Read More.
• Neutral Sentiment: Mesa announced a CEO transition naming Siddhartha Kadia as President & CEO. Leadership change is material — it can drive strategic refocus but may also introduce short‑term volatility until Kadia outlines priorities and execution plans. Read More.
• Negative Sentiment: Analyst skepticism and bearish commentary raise selling pressure: a recent Seeking Alpha piece questions valuation, and summary data show a high P/E and a 100% payout ratio on dividends — factors that heighten concerns about earnings sustainability and upside at current prices. Read More.

Institutional Trading of Mesa Laboratories

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd purchased a new position in Mesa Laboratories during the fourth quarter valued at approximately $27,000. Invesco Ltd. boosted its holdings in shares of Mesa Laboratories by 11.7% in the 4th quarter. Invesco Ltd. now owns 12,845 shares of the medical instruments supplier’s stock worth $1,008,000 after purchasing an additional 1,350 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Mesa Laboratories during the 4th quarter valued at about $989,000. Tudor Investment Corp ET AL raised its holdings in shares of Mesa Laboratories by 332.5% during the 4th quarter. Tudor Investment Corp ET AL now owns 27,426 shares of the medical instruments supplier’s stock valued at $2,153,000 after buying an additional 21,085 shares in the last quarter. Finally, Quadrature Capital Ltd bought a new stake in Mesa Laboratories in the 4th quarter worth approximately $1,062,000. 90.60% of the stock is currently owned by institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.